EKOS in Patients With Pulmonary Embolism (PE)

Beni-Suef University104 enrolled

Overview

A retrospective cohort study assessed patients who underwent EKOS intervention following the failure of initial therapeutic anticoagulation for managing acute pulmonary embolism at a tertiary hospital. Patients aged at least 18 years with a diagnosis of submassive or massive acute PE were included. Patients were excluded if they either did not receive EKOS intervention or were presented with stable PE. The primary outcome was the change in RV/LV diameter ratio from baseline to first outpatient follow-up.

Study Type

OBSERVATIONAL

Enrollment

104

Conditions

Pulmonary Embolism

Interventions

ECOSDRUG

The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE

Control groupDRUG

Alteplase IV infusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ≥ 18 years diagnosed with massive or submassive acute PE. Exclusion Criteria: 1. Patients presented with stable PE 2. Patients did not receive EKOS intervention.

Locations (1)

Saudi German Hospital

Cairo, Egypt

Outcomes

Primary Outcomes

The change in RV/LV diameter ratio

The change in RV/LV diameter ratio from baseline to first outpatient follow-up as documented on an echocardiogram.

Time frame: one month

Secondary Outcomes

All-cause 30-day readmission

Time frame: one month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.